golimumab
Selected indexed studies
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (Lancet Gastroenterol Hepatol, 2023) [PMID:36738762]
- Golimumab. (MAbs, 2009) [PMID:20065639]
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (Gastroenterology, 2014) [PMID:23735746]
_Worker-drafted node — pending editorial review._
Connections
golimumab is a side effect of
Sources
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (2023) pubmed
- Golimumab. (2009) pubmed
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) pubmed
- Golimumab (anti-TNF monoclonal antibody): where we stand today. (2021) pubmed
- Golimumab-Associated Glomerulonephritis. (2021) pubmed
- Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. (2020) pubmed
- Golimumab-induced posterior reversible encephalopathy syndrome (PRES): a case-based review. (2023) pubmed
- Golimumab for the treatment of axial spondyloarthritis. (2017) pubmed
- Golimumab: A Review in Inflammatory Arthritis. (2017) pubmed
- Golimumab in inflammatory bowel diseases: present and future scenarios. (2019) pubmed